



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	266762	Yin Qiao Sang Ju Gan Mao Ling a.k.a. CNF Relief Formula
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Sun Herbal Pty Ltd	
<b>Postal Address</b>	Unit 5/25 Garema Cct, Kingsgrove, NSW, 2208 Australia	
<b>ARTG Start Date</b>	4/01/2016	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Yin Qiao Sang Ju Gan Mao Ling a.k.a. CNF Relief Formula

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	13/12/2019
---------------------	-------------------------	-----------------------	------------

### Permitted Indications

Traditionally used in Chinese medicine to release Exterior  
Traditionally used in Chinese medicine to remove Heat toxin  
Traditionally used in Chinese medicine to disseminate/diffuse lungs/lung-qi  
Traditionally used in Chinese medicine to dispel/expel/extinguish/disperse/clear wind-heat  
Traditionally used in Chinese medicine to decrease/reduce/relieve cough

### Indication Requirements

If TCM terminology is used on medicine label, label statement: Talk to a TCM practitioner/health professional if you are unsure if this medicine is right for you.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must only refer to detoxification in relation to natural body processes.

Product presentation must not imply or refer to disease in any body organ, in particular the kidney or liver.

Product presentation must not imply or refer to serious forms of respiratory disorders/diseases, such as: asthma, pneumonia, COAD, COPD, influenza.

Product presentation must not imply or refer to drugs/alcohol.

Product presentation must not imply or refer to disease in any body organ.

Label statement: Adults only, OR Not to be used in children under 2 years of age without medical advice (or words to that effect).

### Standard Indications

No Standard Indications included on Record

### Specific Indications



**Australian Government**  
**Department of Health**  
**Therapeutic Goods Administration**

No Specific Indications included on Record

#### Warnings

For practitioner dispensing only.

If symptoms persist consult your healthcare practitioner (or words to that effect).

If coughing persists consult your doctor (or a healthcare professional) (or words to that effect).

Adults only. OR Not to be used in children under two years of age without medical advice (or words to that effect).

#### Additional Product information

#### Pack Size/Poison information

##### Pack Size

##### Poison Schedule

#### Components

##### 1 . Formulation 1

**Dosage Form** Capsule, hard

**Route of Administration** Oral

##### Visual Identification

#### Active Ingredients

<b>Chrysanthemum sinense flower Extract dry concentrate</b>	<b>11.19 mg</b>
Equivalent: Chrysanthemum sinense (Dry)	67.14 mg
<b>forsythia suspensa fruit Extract dry concentrate</b>	<b>22.35 mg</b>
Equivalent: forsythia suspensa (Dry)	134.1 mg
<b>Glycine max seed Extract dry concentrate</b>	<b>16.77 mg</b>
Equivalent: Glycine max (Dry)	100.62 mg
<b>Glycyrrhiza uralensis root Extract dry concentrate</b>	<b>9.3 mg</b>
Equivalent: Glycyrrhiza uralensis (Dry)	55.8 mg
<b>Isatis tinctoria root Extract dry concentrate</b>	<b>33.54 mg</b>
Equivalent: Isatis tinctoria (Dry)	201.24 mg
<b>Isatis tinctoria leaf Extract dry concentrate</b>	<b>33.54 mg</b>
Equivalent: Isatis tinctoria (Dry)	201.24 mg
<b>Lonicera japonica flower Extract dry concentrate</b>	<b>33.54 mg</b>
Equivalent: Lonicera japonica (Dry)	201.24 mg
<b>Mentha haplocalyx herb Extract dry concentrate</b>	<b>16.77 mg</b>
Equivalent: Mentha haplocalyx (Dry)	100.62 mg
<b>Morus alba leaf Extract dry concentrate</b>	<b>16.77 mg</b>
Equivalent: Morus alba (Dry)	100.62 mg
<b>Phragmites australis rhizome Extract dry concentrate</b>	<b>22.35 mg</b>
Equivalent: Phragmites australis (Dry)	134.1 mg
<b>Platycodon grandiflorus root Extract dry concentrate</b>	<b>11.19 mg</b>
Equivalent: Platycodon grandiflorus (Dry)	67.14 mg
<b>Prunus armeniaca seed endosperm Extract dry concentrate</b>	<b>16.77 mg</b>
Equivalent: Prunus armeniaca (Dry)	100.62 mg
<b>Saposhnikovia divaricata root Extract dry concentrate</b>	<b>16.77 mg</b>
Equivalent: Saposhnikovia divaricata (Dry)	100.62 mg
<b>Schizonepeta tenuifolia herb top flowering Extract dry concentrate</b>	<b>11.19 mg</b>
Equivalent: Schizonepeta tenuifolia (Dry)	67.14 mg
<b>Scutellaria baicalensis root Extract dry concentrate</b>	<b>27.96 mg</b>
Equivalent: Scutellaria baicalensis (Dry)	167.76 mg

#### Other Ingredients (Excipients)

Agar

Public Summary



**Australian Government**

**Department of Health**  
Therapeutic Goods Administration

carrageenan  
hypromellose  
sodium citrate dihydrate  
soluble maize starch

---

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary